Prosecution Insights
Last updated: August 14, 2026

Cardinal Health 414 LLC

6 pending office actions • 3 art units • 4 examiners • 0 of 6 (0%) have an AI response strategy ready

Portfolio Summary

6
Total Pending OAs
3
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (50%)
3
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (50%)
Multi-statute (no §101)3 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LAU, JONATHAN S 2 63.9% -18.1%
SAMALA, JAGADISHWAR RAO 2 67.9% +55.5%
HANDY, DWAYNE K 1 62.7% +24.9%
VU, JAKE MINH 1 40.7% +27.6%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
17039409 COMPOSITIONS AND RELATED METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS SAMALA, JAGADISHWAR RAO 80d overdue
18189658 Competitive Self-Blocking with Unlabeled Manocept Imaging Agents VU, JAKE MINH 12d
18351905 MANNOSYLATED AMINE DEXTRAN DRUG DELIVERY VEHICLES WITH DEGRADABLE DISULFIDE/CARBONATE LINKERS TARGETING PAYLOADS TO CD206 EXPRESSING CELLS LAU, JONATHAN S 83d

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17039409 COMPOSITIONS AND RELATED METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS SAMALA, JAGADISHWAR RAO 80d overdue
18189658 Competitive Self-Blocking with Unlabeled Manocept Imaging Agents VU, JAKE MINH 12d
18408350 SYSTEMS, METHODS AND DEVICES FOR PRODUCING, MANUFACTURING AND CONTROL OF RADIOPHARMACEUTICALS HANDY, DWAYNE K
17131087 COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME SAMALA, JAGADISHWAR RAO

Top Art Units

Art UnitApps
1618 3
1693 2
1798 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18408350 SYSTEMS, METHODS AND DEVICES FOR PRODUCING, MANUFACTURING AND CONTROL OF RADIOPHARMACEUTICALS HANDY, DWAYNE K 1798 §103 Final Rejection Pending Jan 09, 2024
18351905 MANNOSYLATED AMINE DEXTRAN DRUG DELIVERY VEHICLES WITH DEGRADABLE DISULFIDE/CARBONATE LINKERS TARGETING PAYLOADS TO CD206 EXPRESSING CELLS LAU, JONATHAN S 1693 §102§103 Non-Final OA 83d Pending Jul 13, 2023
18189658 Competitive Self-Blocking with Unlabeled Manocept Imaging Agents VU, JAKE MINH 1618 §103§112 Non-Final OA 12d Pending Mar 24, 2023
18148023 METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS LAU, JONATHAN S 1693 §103Other Non-Final OA 28d overdue Pending Dec 29, 2022
17131087 COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME SAMALA, JAGADISHWAR RAO 1618 §103 Final Rejection Pending Dec 22, 2020
17039409 COMPOSITIONS AND RELATED METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS SAMALA, JAGADISHWAR RAO 1618 §103§112Other Final Rejection 80d overdue Pending Sep 30, 2020

Managing Cardinal Health 414 LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month